Jazz Pharmaceuticals plc (JAZZ) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Dublin, Ireland. Le PDG actuel est Renee D. Gala.
JAZZ a date d'introduction en bourse 2007-06-01, 2,800 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $12.38B.
Jazz Pharmaceuticals plc is a biopharmaceutical company headquartered in Dublin, Ireland, that identifies, develops, and commercializes pharmaceutical products to address unmet medical needs across the United States, Europe, and international markets. The company maintains a focused portfolio in neuroscience—particularly sleep medicine and movement disorders—and oncology, including hematologic and solid tumors. Key marketed products include Xyrem and Sunosi for narcolepsy-related conditions, Erwinaze for acute lymphoblastic leukemia, Defitelio for hepatic veno-occlusive disease, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer. The company also advances several late-stage candidates, including Xywav for narcolepsy and hypersomnia, and compounds targeting essential tremor and post-traumatic stress disorder. Jazz Pharmaceuticals operates through strategic licensing and collaboration agreements with biotechnology partners to enhance its clinical and commercial capabilities.
